173 related articles for article (PubMed ID: 32391884)
1. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
Tulstrup M; Moriyama T; Jiang C; Grosjean M; Nersting J; Abrahamsson J; Grell K; Hjalgrim LL; Jónsson ÓG; Kanerva J; Lund B; Nielsen SN; Nielsen RL; Overgaard U; Quist-Paulsen P; Pruunsild K; Vaitkeviciene G; Wolthers BO; Zhang H; Gupta R; Yang JJ; Schmiegelow K
Blood; 2020 Sep; 136(10):1161-1168. PubMed ID: 32391884
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Leclerc GJ; Mou C; Leclerc GM; Mian AM; Barredo JC
Leukemia; 2010 Mar; 24(3):552-62. PubMed ID: 20072153
[TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
4. Association of
Kodidela S; Dorababu P; Thakkar DN; Dubashi B; Sundaram R; Muralidharan N; Nidanapu RP; Aribandi A; Pradhan SC; Uppugunduri CRS
Genes (Basel); 2020 May; 11(6):. PubMed ID: 32481505
[TBL] [Abstract][Full Text] [Related]
5. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
6. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
Galpin AJ; Schuetz JD; Masson E; Yanishevski Y; Synold TW; Barredo JC; Pui CH; Relling MV; Evans WE
Mol Pharmacol; 1997 Jul; 52(1):155-63. PubMed ID: 9224825
[TBL] [Abstract][Full Text] [Related]
7. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia.
Lin JT; Tong WP; Trippett TM; Niedzwiecki D; Tao Y; Tan C; Steinherz P; Schweitzer BI; Bertino JR
Leuk Res; 1991; 15(12):1191-6. PubMed ID: 1722550
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
12. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.
Barredo JC; Synold TW; Laver J; Relling MV; Pui CH; Priest DG; Evans WE
Blood; 1994 Jul; 84(2):564-9. PubMed ID: 7517720
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.
Lopez-Lopez E; Autry RJ; Smith C; Yang W; Paugh SW; Panetta JC; Crews KR; Bonten EJ; Smart B; Pei D; McCorkle JR; Diouf B; Roberts KG; Shi L; Pounds S; Cheng C; Mullighan CG; Pui CH; Relling MV; Evans WE
J Clin Invest; 2020 Dec; 130(12):6600-6615. PubMed ID: 33164984
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia.
Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
Cancer Chemother Pharmacol; 2014 Aug; 74(2):283-9. PubMed ID: 24908438
[TBL] [Abstract][Full Text] [Related]
15. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
[TBL] [Abstract][Full Text] [Related]
16. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias.
Longo GS; Gorlick R; Tong WP; Lin S; Steinherz P; Bertino JR
Oncol Res; 1997; 9(5):259-63. PubMed ID: 9306433
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Whitehead VM; Vuchich MJ; Lauer SJ; Mahoney D; Carroll AJ; Shuster JJ; Esseltine DW; Payment C; Look AT; Akabutu J
Blood; 1992 Sep; 80(5):1316-23. PubMed ID: 1381244
[TBL] [Abstract][Full Text] [Related]
18. Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
Kodidela S; Pradhan SC; Dubashi B; Basu D
Eur J Clin Pharmacol; 2015 Nov; 71(11):1349-58. PubMed ID: 26335211
[TBL] [Abstract][Full Text] [Related]
19. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.
Belkov VM; Krynetski EY; Schuetz JD; Yanishevski Y; Masson E; Mathew S; Raimondi S; Pui CH; Relling MV; Evans WE
Blood; 1999 Mar; 93(5):1643-50. PubMed ID: 10029593
[TBL] [Abstract][Full Text] [Related]
20. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
Synold TW; Relling MV; Boyett JM; Rivera GK; Sandlund JT; Mahmoud H; Crist WM; Pui CH; Evans WE
J Clin Invest; 1994 Nov; 94(5):1996-2001. PubMed ID: 7525652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
